ACTRN12613001020774尚未招募3 期
Intravitreal aflibercept for the treatment of previously treated exudative age related macular degeneration
Greenlane Clinical Centre Auckland District Health Board0 个研究点目标入组 50 人开始时间: 2013年9月13日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Ability to provide informed consent and complete study assessments
- •2. Age 50 years or older
- •3. CNV secondary to AMD
- •4. Best corrected baseline visual acuity between 6/6 to 6/60 on ETDRS chart
- •5. Presence of subretinal fluid or cystic intraretinal oedema on spectral domain OCT (SD-OCT) [Spectralis] after at least four anti-VEGF treatments within minimum of 6 months and maximum of 5 years before enrollment of the study.
- •6. Documentation of the presence of subretinal fluid or cystoid oedema less than 42 days since last treatment with an antiVegf agent.
排除标准
- •1. Pregnancy or lactation
- •2. Premenopausal women not using contraception
- •3. Prior anti-VEGF injection in the study eye within 30 days of baseline
- •4. Prior treatment with photo dynamic therapy (PDT) within 90 days of baseline and more than 6 prior PDT treatments
- •5. Significant subretinal fibrosis or atrophy
- •6. Prior treatment with triamcinolone in the study eye within six months of baseline
- •7. Intraocular surgery in the study eye within 2 months of baseline
- •8. Prior vitrectomy or other surgical intervention for AMD in the study eye
研究者
相似试验
已完成
不适用
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
尚未招募
不适用
Intravitreal aflibercept injection for exudative age-related macular degeneratioAge-Related Macular DegenerationJPRN-UMIN000010997Department of Ophthalmology, Fukushima Medical University School of Medicine50
已完成
4 期
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
进行中（未招募）
1 期
Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumChoroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticumMedDRA version: 20.0Level: PTClassification code 10037150Term: Pseudoxanthoma elasticumSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-005263-33-DEMedizinische Fakultät der Universität Bonn15
招募中
不适用
Treat and extend regimens with intravitreal aflibercept for macular edema secondary to branch retinal vein occlusiobranch retinal vein occlusionJPRN-UMIN000027005Jikei daisan hospital50